SERA PROGNOSTICS, INC.SERAEarnings & Financial Report
Nasdaq · Health Care · Services-Medical Laboratories
Sera Prognostics, Inc. is a women's health diagnostics company dedicated to developing and commercializing evidence-based clinical tests to improve pregnancy and neonatal health outcomes. Its core products include precision preterm birth risk assessment tests, serving healthcare providers, maternal health partners and patients mainly across the United States.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 17.90% | 5.4M | — | 2024-01-10 |
| NOS. OF ABOVE PERSONS | 9.40% | 3.0M | ▲ +2.90pp | 2024-11-14 |
| aMoon Growth Fund Limited Partnership | 5.73% | 1.9M | ▼ -3.77pp | 2024-11-04 |
| Vivo | 5.40% | 1.7M | — | 2024-02-13 |
| of Above Person | 4.30% | 1.3M | — | 2024-01-26 |
| InterWest Partners X, LP | 0.40% | 126.3K | — | 2024-01-19 |
Insider Transactions
Net 90d: −$103.9K · buys $0 / sells $103.9KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-12 | Zhenya Lindgardt | Chief Executive Officer | Grant | 154.4K | $0.00 | $0 |
| 2026-03-12 | Benjamin Jackson | General Counsel | Grant | 44.2K | $0.00 | $0 |
| 2026-03-12 | Anderson Dyaarl Lee Jr. | Chief Commercial Officer | Grant | 12.5K | $0.00 | $0 |
| 2026-03-12 | Austin Aerts | Chief Financial Officer | Grant | 44.2K | $0.00 | $0 |
| 2026-03-12 | Inglis Tiffany Eul Davis | Chief Medical Officer | Grant | 17.4K | $0.00 | $0 |
| 2026-03-11 | Austin Aerts | Chief Financial Officer | Sell (open market) | 1.0K | $2.04 | $2.1K |
| 2026-03-11 | Harrison Robert Gardner | Chief Information Officer | Sell (open market) | 716 | $2.04 | $1.5K |
| 2026-03-11 | Boniface John J. | Chief Scientific Officer | Sell (open market) | 1.5K | $2.04 | $3.1K |
| 2026-03-11 | Benjamin Jackson | General Counsel | Sell (open market) | 1.0K | $2.04 | $2.1K |
| 2026-03-11 | Paul Kearney | Chief Data Officer | Sell (open market) | 1.4K | $2.04 | $2.8K |
1–10 of 22
Page 1 / 3